Essex Investment Management’s ImmuCell ICCC Stock Holding History

Essex Investment Management’s Portfolio ICCC Stock Details ICCC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-31,969	Closed	-$224K	–	411
2018 Q1	$224K	Sell	31,969 -3,236	-9%	-$23.7K	0.03%	344
2017 Q4	$309K	Buy	35,205 +8,494	+32%	+$69.5K	0.04%	318
2017 Q3	$174K	Buy	26,711 +16,249	+155%	+$106K	0.02%	345
2017 Q2	$77K	Buy	+10,462	New	+$62.1K	0.01%	337

Other funds holding ICCC

Heartland Advisors Milwaukee, Wisconsin $1.96B AUM 28.26% 1-Year Est. Return

PCM

Perritt Capital Management Chicago, Illinois $59.8M AUM 26.94% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SRC

Shufro Rose & Co New York $1.47B AUM 19.38% 1-Year Est. Return

EFS

Essex Financial Services Essex, Connecticut $1.78B AUM 23.37% 1-Year Est. Return

Minerva Advisors Bala Cynwyd, Pennsylvania $155M AUM 35.49% 1-Year Est. Return

RBF Capital San Francisco, California $2.05B AUM 29.64% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Essex Investment Management's ICCC Position: Q2 2018 in Review

Essex Investment Management sold out of ImmuCell (ICCC) in Q2 2018, closing a stake of 31,969 shares — an estimated $224K sold.

Essex Investment Management first reported a position in ICCC in Q2 2017 and held it in 4 quarters. The position peaked at $309K in Q4 2017. 18 funds tracked by Wall St. Rank hold ICCC as of Q2 2018.

Essex Investment Management reported no remaining ImmuCell position as of Q2 2018 after selling out during the quarter.
Essex Investment Management sold 31,969 ImmuCell shares in Q2 2018, an estimated $224K.
Essex Investment Management first reported a position in ImmuCell in Q2 2017 and held it in 4 quarters.
Essex Investment Management's ImmuCell position peaked at $309K in Q4 2017.
18 funds tracked by Wall St. Rank held ImmuCell as of Q2 2018.

Based on Essex Investment Management's 13F filing for Q2 2018, filed 17 Jul 2018.